A 38-year-old man with systemic lupus erythematosus (SLE) is started on mycophenolate mofetil (MMF) 1 g twice daily for lupus nephritis (Class IV). After 3 months of therapy, he presents with fever (38.5°C), productive cough, and bilateral interstitial infiltrates on chest X-ray. Bronchoalveolar lavage (BAL) shows Pneumocystis jirovecii. CD4 count is 180 cells/μL. What is the most appropriate immediate action?

Explanation

## Clinical Scenario Analysis The patient presents with opportunistic infection (PCP) in the setting of severe immunosuppression from MMF monotherapy for SLE. **Key Clinical Features:** - CD4 count 180 cells/μL (profound immunosuppression; normal >500) - Pneumocystis jirovecii pneumonia (PCP) — hallmark of severe cell-mediated immunosuppression - Timing: 3 months into MMF therapy - Underlying autoimmune disease (SLE) requiring continued immunosuppression ## Mechanism of MMF-Induced Immunosuppression **High-Yield:** MMF inhibits IMPDH (inosine monophosphate dehydrogenase), preferentially affecting T and B lymphocyte proliferation. However, at high doses or in certain patients, it can cause profound immunosuppression leading to opportunistic infections. **Mnemonic: IMPDH** — **I**nosine **M**onophosphate **D**ehydrogenase **H**ypoxanthine-guanine phosphoribosyltransferase pathway inhibition. ## Management of MMF-Related Opportunistic Infection ```mermaid flowchart TD A[Opportunistic infection on MMF]:::outcome --> B{Severity & CD4 count?}:::decision B -->|CD4 < 200 + severe infection| C[STOP MMF immediately]:::urgent B -->|CD4 200-350 + mild infection| D[Reduce MMF dose]:::action C --> E[Treat infection: TMP-SMX for PCP]:::action D --> E E --> F[Initiate PCP prophylaxis]:::action F --> G{After recovery?}:::decision G -->|Consider alternative| H[Switch to azathioprine or lower-dose MMF]:::action G -->|Maintain SLE control| I[Restart MMF cautiously at lower dose]:::action ``` ## Immunosuppressant Comparison in SLE with OI | Agent | OI Risk | Mechanism | Role in SLE | Action | |-------|---------|-----------|-------------|--------| | **MMF (high dose)** | Very high (IMPDH inhibition) | T/B cell suppression | Standard for lupus nephritis | **STOP** if severe OI | | **Azathioprine** | Moderate (6-MP metabolite) | Purine synthesis inhibition | Alternative for lupus | **Switch to** after OI recovery | | **Cyclosporine** | Moderate (calcineurin inhibition) | T cell suppression | Not preferred for lupus | Not recommended; does not reduce OI risk | | **Prednisolone** | Dose-dependent | Broad immunosuppression | Adjunct in lupus | Continue at lowest effective dose | ## Rationale for Stopping MMF **Clinical Pearl:** When a patient develops a serious opportunistic infection (OI) while on MMF: 1. **Immediate action**: Discontinue MMF to allow immune reconstitution 2. **Treat the infection**: Start appropriate antimicrobial therapy (TMP-SMX for PCP) 3. **Prevent recurrence**: Initiate PCP prophylaxis (TMP-SMX or pentamidine) until CD4 >200 for ≥3 months 4. **Restart immunosuppression**: After clinical and immunological recovery, consider alternative agents (azathioprine, lower-dose MMF, or mycophenolate sodium) **Warning:** Continuing MMF while treating PCP is dangerous — the patient remains profoundly immunosuppressed and at risk for treatment failure and disseminated infection. ## Why Other Options Are Incorrect - **Continuing MMF** (Option A) perpetuates severe immunosuppression and increases mortality risk from PCP - **Dose reduction alone** (Option C) is insufficient for CD4 <200; the agent must be stopped - **Switching to cyclosporine** (Option D) does not reduce OI risk and is not preferred for lupus; it provides no advantage over continuing MMF [cite:Harrison 21e Ch 197; KD Tripathi 8e Ch 72]